Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Abstract Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA) on the PK of the immune checkpoint inhibitor atezol...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2022-01-01
|
| Col·lecció: | Clinical and Translational Science |
| Accés en línia: | https://doi.org/10.1111/cts.13127 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|